{"name":"Nicox Ophthalmics, Inc.","slug":"nicox-ophthalmics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"AC-170 Vehicle","genericName":"AC-170 Vehicle","slug":"ac-170-vehicle","indication":"Ocular hypertension or glaucoma (Phase 3 development)","status":"phase_3"},{"name":"NCX 470 0.1%","genericName":"NCX 470 0.1%","slug":"ncx-470-0-1","indication":"Open-angle glaucoma","status":"phase_3"}]}],"pipeline":[{"name":"AC-170 Vehicle","genericName":"AC-170 Vehicle","slug":"ac-170-vehicle","phase":"phase_3","mechanism":"AC-170 Vehicle is a formulation component designed to deliver the active pharmaceutical ingredient AC-170 to ocular tissues.","indications":["Ocular hypertension or glaucoma (Phase 3 development)"],"catalyst":""},{"name":"NCX 470 0.1%","genericName":"NCX 470 0.1%","slug":"ncx-470-0-1","phase":"phase_3","mechanism":"NCX 470 is a nitric oxide-donating prostaglandin F analog that lowers intraocular pressure by increasing uveoscleral outflow and releasing nitric oxide to enhance trabecular outflow.","indications":["Open-angle glaucoma","Ocular hypertension"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQbk91SWw5cmEtMzhiRXhJNmRsVnpBaWhfcXg0T0h5Szh4Tm1zSGk0V1h1emxUcVRmaVgyczdpM1ZXXzJFYVBvWXRuNGpXckd1NjJzWmU0ZVFNMmpJSFl6dTFDR0I3Zzk0VURWZmo0bGl1Zl9hbHhOY1k3elhSNXlXM09HeDlMNk5mSFlZajQxSDctOGl5c0ZtYm9fbnZ6aEU?oc=5","date":"2026-04-03","type":"earnings","source":"openPR.com","summary":"Open Angle Glaucoma Market: Expanding Revenue Landscape to 2034 - openPR.com","headline":"Open Angle Glaucoma Market: Expanding Revenue Landscape to 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxNeFVfZ1F2LWFobnBLNENTMHJUZ2tTUkMtT2JTSXNlOG04NHdlbDN0c2dWcldFaWYzakxuNjRnc0Q1TWJ1VndOSWVhblpUazd1bGhXbGhxUWhRNi1HZVpHalBJbVc0QVRhMXVjSlMtdHJHUEdmME1OcTktb0tDUEY5OXVWZU1sQ1NxYURrUWdEYzZucjVDNmJjZXZhOGRjMUxVMEc4RHFsMGF1SEl4NVMwdTk3NEt1SW1kWkpEb2UwbHRWbVpNbHRiNmhnWlBXVkJxeWR1SWZ4a0k1UlZ5dmpSWllSU29tSU92NXc?oc=5","date":"2026-03-24","type":"pipeline","source":"Barchart.com","summary":"Ocular Hypertension Pipeline Demonstrates Strong Momentum with 50+ Companies Advancing 75+ Therapies | DelveInsight - Barchart.com","headline":"Ocular Hypertension Pipeline Demonstrates Strong Momentum with 50+ Companies Advancing 75+ Therapies | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxOTlQzRkpQQlZDZXVlTFU3RzJWVV9HN3RhdWxyQ1gxdGJDaHFvZWpFQy1tOWRDbXhESDk2RkVWajdQZ2NhSTFncGlxTF9WTEVXMTdYZlhWdmd6NVI3b1FTbGdCZjNGTXBrVWp3S19GUF9DZlh0OFF3RXI0cU1XMFZhVXFzZjJZVkNpUU95bm9Jc0Y3Sm9yMkFoQ1dTTzNPb29PY0MwZ2VWaXJNR3d0WHgtY1BXV0FFWlMzZFRwdGl6VmR5U2xGMUNSLTRLdm9UQ2p6dVlvYU1BemYySTVLTE5va3ZFdmxvb0thRXNUNzlCVWJld0VuUDZn?oc=5","date":"2025-09-09","type":"pipeline","source":"PR Newswire","summary":"Open-Angle Glaucoma Market Outlook Brightens as Emerging Therapies Reshape Treatment Paradigms | DelveInsight - PR Newswire","headline":"Open-Angle Glaucoma Market Outlook Brightens as Emerging Therapies Reshape Treatment Paradigms | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxQMHhfSGI1a3NjMkNsRC1ZdkRNUzJnS0FnMkhZbFBiRWF2Ykp0cHlVQ3IyZVRsZWNQQjNEaW5ESUd5V0ktU3NYYnI4NHAxT0tDLVFQZ0dDMlhyekNqZzI4RnRhX3FXV3VnX1VFODIwMkRvdUwxMEJqRlBjNnkwRktlODhwSEJOWEVVaERzXzlPTGdpSDNITmpFWXdjYldwUHkwWXVldjZXSkp6N3lZWC1LOEtqOGJRY05NdU52V1JFejhKX1BFS3NXRG1wd0NnckxyNmdIRWxoUGVnalJOeWp3Rl9TaDNHYThTOHc?oc=5","date":"2025-03-25","type":"pipeline","source":"PR Newswire","summary":"ROCKLATAN/ROCLANDA Strengthens Market Position with Robust Sales and Patient Outcomes | DelveInsight - PR Newswire","headline":"ROCKLATAN/ROCLANDA Strengthens Market Position with Robust Sales and Patient Outcomes | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxONzJwRzBpN1dGQ1h1QkRLdEFDQnRrcTJhMUkwSTJRdk9uZWJkVUZOd2VNel8tTWlJYzZkSzdJSG9nRXRuZFpkVFpEV1RKMDBvTWlkNnRaN3BzVUU5SWdZZDVwc1djWWhEaVhPRjlxWS15RDRJbm9hS29hQllqQktObGtUTDZ6OHlRQ2F4ZGlNQzFRUlpNakd2MkdiU244N3hLX3lka3FHS3VoTlVtbzJ2LXk2UHJ0ckZ5VjdGUi1MSUFRaU5YX2kxb2tOUnJoUFItM256NTFaaHhRSlpFRjdNVWE1eEZmY3RzdW5LZmZGcmI4dEVaNFlWcmZFQ3RXRVhfaGctMVhYTm9pdVMyaUx4ZC1feDh1SGk2czRLRUJzaDQydWVlWUdQUFR6bzJ5c09PaUtCWFNoQQ?oc=5","date":"2025-02-26","type":"pipeline","source":"GlobeNewswire","summary":"DURYSTA’s Market Potential Across the 7MM is Set to Soar - GlobeNewswire","headline":"DURYSTA’s Market Potential Across the 7MM is Set to Soar","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNakxzNUFGZ0VUdVhiZXI4X1hfTmVMMjNjQlY2NFpGaHdWRDNGNm56UkJjcnBWMHJPckdmWmRnbVJlOGtnTUl0b2hoSWhaSGdoSmlDLWo3amMwdVhETXRFQ0ZkQldNMmdhWUtCVHhKaG9pMUdncGloNDBrbkYySDYxSDNhVEp1NDIwQ2RHOXo2QldlSl9LeHdFV056cHlsbnFXOTNNTHlGbG4?oc=5","date":"2025-02-20","type":"pipeline","source":"BioSpace","summary":"U.S. Ophthalmic Drugs Market Size to Hit USD 33.51 Billion by 2033 - BioSpace","headline":"U.S. Ophthalmic Drugs Market Size to Hit USD 33.51 Billion by 2033","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxQeHhISHVyb2Z5d2h0aGoyZW4takJhLTlQaDlYbFFlaTRvMnBrN3h6cEttemhWelM0SzRkRFlzVlkzTkdET1dqb2xZcVdjZ0pKWGZIVnd0QnBDRHJjN0J3WXZmaWRpU0g4VndCYk9zSE94dF80VWNWX01MYXpJci02SFozdHlOdlR2TkM0ckNpdjBzVHE5U2hVUzc0U0dMODBXZkNYY08xOFh1OE53eWRRYi03cUIwQlh3d0JvTU41djhNMm9Mc3hBelZldmRETjlQd3ptNmlkY2RuQm9zR1F4WlMzeVQyUnhxeDdBSUNSbjRJX1NLVjI0ZEs0bmY3dWh4dDd1TFZKbjlpNTlIeXdqdm9PWG1mS3hEMTNTTmRjZw?oc=5","date":"2025-01-20","type":"trial","source":"GlobeNewswire","summary":"Advancements in Ocular Hypertension Clinical Trial Pipeline - GlobeNewswire","headline":"Advancements in Ocular Hypertension Clinical Trial Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxQc0dmbjlSLUdVUTl2OFVxOHFiRS1waGI3cGxFazdlVmxpUDNMNjh2dnVPWkxhckMzaDZGVzZHUDMtdGllVmZSMy1XcnNVYjVkbGtqeC1wZ2ZpMm15NHhWOWpYTTFad1hSeUk2c2syZlJ6RnNMTTdPMy1ETjkyaVY4NlUtLUc?oc=5","date":"2020-07-10","type":"pipeline","source":"Ophthalmology Times","summary":"New molecule for allergic conjunctivitis makes debut - Ophthalmology Times","headline":"New molecule for allergic conjunctivitis makes debut","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxOZ1l4X3czWXpzb2MyWU9wM2RNWUVQTm00Um1jNGtzYXh6c3ZEdjIzWFREbWY5cWhWaVNDci1aYm1XNlRvOVAyYVFTNEVjRUxjMVZOZGZlYktOMWpwYXpHaGp5VzNIZzJoMVpZTGdBZ3EwMUpmRFFzMlhUeEN1Wi1HNkpXV1d3dWdoSllyenVBVWtFWnFyc0I2OXEzRFhIM2pYaG02RG5LTXNCSmZMOGxlUFRvNW8wcmlkOXJTMGY5NFRjaVJ6aFhBTHNVeGtDTkxTVHFmTEZ1S0lzUTRhOEtndkI4Nk9OY2FiRWpYdDVB?oc=5","date":"2017-11-02","type":"regulatory","source":"PR Newswire","summary":"Bausch + Lomb And Nicox Announce FDA Approval Of VYZULTA™ (Latanoprostene Bunod Ophthalmic Solution), 0.024% - PR Newswire","headline":"Bausch + Lomb And Nicox Announce FDA Approval Of VYZULTA™ (Latanoprostene Bunod Ophthalmic Solution), 0.024%","sentiment":"positive"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}